Skip to content
lifestyle.tasteterminal.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Jaguar Health, Inc.
Jaguar Health Regains Compliance with Nasdaq’s Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq’s Bid Price Rule
May 23, 2026
Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
May 22, 2026
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health
May 22, 2026
Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs
May 21, 2026
Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq’s Bid Price Rule; Company Announces Reverse Stock Split
May 20, 2026
Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)
May 20, 2026
Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders
April 20, 2026
Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health’s Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs
April 13, 2026
Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates
April 9, 2026
Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
April 8, 2026
←
Previous Page
1
2
3
4
Next Page
→